Literature DB >> 8400937

Erythroderma after clodronate treatment.

I Pajus1, P Lestang, F Lioté, A Dryll.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8400937      PMCID: PMC1678770          DOI: 10.1136/bmj.307.6902.484

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  4 in total

1.  Severe reaction to diphosphonate: implications for treatment of Paget's disease.

Authors:  A T Elliott; T Murray; R M Mackie; J A Hunter
Journal:  BMJ       Date:  1988-09-03

2.  [Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France].

Authors:  B Bégaud; J C Evreux; J Jouglard; G Lagier
Journal:  Therapie       Date:  1985 Mar-Apr       Impact factor: 2.070

3.  Side effects of disodium aminohydroxypropylidenediphosphonate (APD) during treatment of bone diseases.

Authors:  C A Mautalen; C A Casco; D Gonzalez; G R Ghiringhelli; C Massironi; G A Fromm; L Plantalech
Journal:  Br Med J (Clin Res Ed)       Date:  1984-03-17

Review 4.  Tolerability and safety of clodronate therapy in bone diseases.

Authors:  M Mian; F Beghé; A Caprio; R Aloj; A Bertelli
Journal:  Int J Clin Pharmacol Res       Date:  1991
  4 in total
  2 in total

Review 1.  Adverse effects of bisphosphonates. A comparative review.

Authors:  S Adami; N Zamberlan
Journal:  Drug Saf       Date:  1996-03       Impact factor: 5.606

Review 2.  Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  G L Plosker; K L Goa
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.